Biologic drugs — used to treat diseases such as rheumatoid arthritis and cancer — accounted for 70 percent of the growth in U.S. prescription drug spending from 2010 to 2015. Policymakers in Washington, including the FDA’s Scott Gottlieb, are pushing biosimilars as a way to introduce competition into the biologics market and restrain their price increases — and have recently released a slate of policies intended to reinvigorate the market.

But the experience so far raises questions about the effectiveness of this strategy: Many biosimilars approved by the FDA have not made it onto the U.S. market, even as they’re being sold in Europe, while other biosimilars have been approved by European regulators but not by the FDA. STAT senior writer and Pharmalot columnist Ed Silverman and STAT Washington correspondent Nick Florko discussed why.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy